Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Bronchiolitis Obliterans. According to GlobalData, Phase II drugs for Bronchiolitis Obliterans does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Itacitinib adipate LoA Report. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Itacitinib adipate overview

Itacitinib adipate (INCB-39110) is under development for the treatment of cytokine release syndrome, advanced solid tumor malignancies including sporadic hemophagocytosis lymphohistiocytosis (HLHs), advanced hepatocellular carcinoma, T-Cell Leukemia,   soft tissue sarcoma such as leiomyosarcoma, synovial sarcoma, pleomorphic undifferentiated sarcoma, myxoid or round cell liposarcoma, transitional cell carcinoma, primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF), post essential thrombocythemia myelofibrosis (PET-MF), B-cell lymphomas including indolent, aggressive B-cell non- Hodgkin's lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, diffuse large B-cell lymphoma, Hodgkin's lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms, relapsed and refractory overlap syndromes, metastatic non-small cell lung cancer, acute myeloid leukemia(AML), acute lymphocytic leukemia (ALL). The drug candidate is administered orally as a tablet. INCB-39110 targets Janus kinase 1 (JAK1).
The drug candidate was also under development for pancreatic ductal adenocarcinoma, moderate to severe ulcerative colitis, renal cell carcinoma, rheumatoid arthritis, chronic plaque psoriasis, endometrial cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma, colorectal cancer, triple negative breast cancer, small cell lung cancer, urothelial cancer, ureter cancer, bladder, urethral cancer, post-lung transplant bronchiolitis obliterans syndrome (BOS) and acute graft versus host disease.

Incyte overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Incyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

For a complete picture of Itacitinib adipate’s drug-specific PTSR and LoA scores, buy the report here.